MX2023009620A - Metodos terapeuticos. - Google Patents

Metodos terapeuticos.

Info

Publication number
MX2023009620A
MX2023009620A MX2023009620A MX2023009620A MX2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A MX 2023009620 A MX2023009620 A MX 2023009620A
Authority
MX
Mexico
Prior art keywords
therapeutic methods
present disclosure
inclusive
administering
dose
Prior art date
Application number
MX2023009620A
Other languages
English (en)
Inventor
Barry S Coller
C Michael Gibson
Hof Arnoud W J Van''t
Original Assignee
Celecor Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celecor Therapeutics Inc filed Critical Celecor Therapeutics Inc
Publication of MX2023009620A publication Critical patent/MX2023009620A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727Heparin; Heparan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente descripción se refiere a un método para el tratamiento o la prevención de un trastorno trombótico, que comprende administrar a un sujeto que lo necesita una cantidad eficaz del Compuesto (1), o una sal farmacéuticamente aceptable de este, en una dosis en el intervalo de 0.01-0.3 mg/kg, inclusive. La presente descripción se refiere, además, a composiciones para su uso en dicho método.
MX2023009620A 2021-02-17 2022-02-16 Metodos terapeuticos. MX2023009620A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163150301P 2021-02-17 2021-02-17
PCT/US2022/016571 WO2022177968A1 (en) 2021-02-17 2022-02-16 Therapeutic methods

Publications (1)

Publication Number Publication Date
MX2023009620A true MX2023009620A (es) 2023-11-01

Family

ID=82931154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009620A MX2023009620A (es) 2021-02-17 2022-02-16 Metodos terapeuticos.

Country Status (9)

Country Link
EP (1) EP4294402A1 (es)
JP (1) JP2024507294A (es)
KR (1) KR20230157354A (es)
CN (1) CN117098538A (es)
AU (1) AU2022224562A1 (es)
BR (1) BR112023016459A2 (es)
CA (1) CA3211215A1 (es)
MX (1) MX2023009620A (es)
WO (1) WO2022177968A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104936598B (zh) * 2012-01-16 2017-11-03 洛克菲勒大学 化合物、药物组合物及其用途
EP3810134A4 (en) * 2018-06-19 2022-03-30 Celecor Therapeutics, Inc. DEUTERED RUC-4

Also Published As

Publication number Publication date
EP4294402A1 (en) 2023-12-27
KR20230157354A (ko) 2023-11-16
CA3211215A1 (en) 2022-08-25
CN117098538A (zh) 2023-11-21
AU2022224562A1 (en) 2023-08-31
WO2022177968A1 (en) 2022-08-25
JP2024507294A (ja) 2024-02-16
BR112023016459A2 (pt) 2023-10-10
WO2022177968A8 (en) 2022-11-17
WO2022177968A9 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MX2018003331A (es) Administracion de potenciadores de regulador de la conductancia transmembrana de fibrosis quistica (cftr) deuterados.
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
TW200639159A (en) Treatment of pain
MX2021015854A (es) Composiciones y métodos para tratar trastornos del snc.
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
MY150682A (en) Method for using vasopressin antagonist with anthracycline chemotherapy agents to reduce cardiotoxicity and/or improve survival
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
MX2022003845A (es) Tratamientos cognitivos medicinales.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
CA2595363A1 (en) Methods and materials with trans-clomiphene for the treatment of male infertility
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
MX2023013225A (es) Inhibidores de la cinasa 4 similar a polo.
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
MX2024002409A (es) Terapias contra el cancer.
PH12020551117A1 (en) Compositions for preventing or treating uveitis
MX2023011203A (es) Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular.
MX2023009620A (es) Metodos terapeuticos.
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2022005029A (es) Metodos de tratamiento y/o prevencion de acontecimientos cardiovasculares adversos graves (mace) con una combinacion de un inhibidor de bromodominio y extraterminal (bet) y un inhibidor de transporte de glucosa dependiente de sodio 2.
MX2023004435A (es) Compuestos y composiciones para el tratamiento de la criptosporidiosis.
MX2023004516A (es) Uso de pridopidina y analogos para el tratamiento de la ansiedad y la depresion.
PH12020551620A1 (en) Compositions for preventing or treating dry eye
MX2021015390A (es) Tratamiento para sinucleinopatias.